H1 Insights

Founded in 2017 by Daniel Imfeld and Ian Sax and headquartered in New York, US, H1 Insights, Inc. focuses on delivering comprehensive data solutions for healthcare operations. In January 2025, H1 Insights, Inc. acquired Ribbon Health from Andreessen Horowitz, BoxGroup, Gaingels, General Catalyst Partners, and Rock Health. The company has successfully completed five deals to date, indicating its commitment to growth and expansion within the healthcare sector. In May 2026, H1 Insights, Inc. H1 offers a comprehensive suite of data analytics and software solutions designed to enhance the efficiency of healthcare operations. Their core product offerings focus on optimizing clinical trials and medical affairs through real-time insights into healthcare professionals (HCPs), patient demographics, and clinical data. The platform analyzes information pertaining to over 11 million healthcare professionals, aiding clients in identifying suitable doctors for clinical trials, enhancing patient representation in studies, and streamlining site selection processes. These products serve a diverse client base that includes life sciences companies, health plans, and medical affairs teams across various geographical markets, including North America, Europe, and Asia. By integrating advanced analytics and AI-driven insights, H1 aims to empower its users to make informed decisions that ultimately improve patient care and outcomes. The revenue structure of H1 primarily revolves around a subscription-based model, where clients gain access to their suite of software and data solutions through various pricing plans tailored to their needs. These transactions typically involve partnerships with healthcare organizations, life sciences companies, and medical institutions, allowing for direct access to valuable clinical intelligence. Specific services, such as the HCP Universe and Clinical Intelligence Streams, are central to client operations, enabling efficient management of provider data and engagement strategies. H1's clients benefit from these offerings through enhanced decision-making capabilities, which translate into improved operational efficiency in clinical trials and medical engagements. The company strategically positions itself within the healthcare ecosystem, ensuring that its products address the pressing needs of its customer base while facilitating impactful healthcare outcomes.

1. Series D

   May 28, 2026

   Amount

   $40M

   Investors

   Locked

2. Series C

   Jun 10, 2022

   Amount

   $22M

   Investors

   Locked

3. Series C

   Nov 15, 2021

   Amount

   $99M

   Investors

   Locked

4. Series B

   Dec 17, 2020

   Amount

   $55M

   Investors

   Locked

5. Series B

   Dec 17, 2020

   Amount

   $58M

   Investors

   Locked

6. Series A

   Mar 22, 2020

   Amount

   $13M

   Investors

   Locked